Voriconazole for candidosis: an important addition?
- 1 October 2005
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 366 (9495) , 1413-1414
- https://doi.org/10.1016/s0140-6736(05)67579-4
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trialThe Lancet, 2005
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- Evaluation of the Etest and Disk Diffusion Methods for Determining Susceptibilities of 235 Bloodstream Isolates of Candida glabrata to Fluconazole and VoriconazoleJournal of Clinical Microbiology, 2003
- Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal InfectionsClinical Infectious Diseases, 2003
- Comparison of Caspofungin and Amphotericin B for Invasive CandidiasisNew England Journal of Medicine, 2002
- Voriconazole versus Amphotericin B for Primary Therapy of Invasive AspergillosisNew England Journal of Medicine, 2002
- Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent FeverNew England Journal of Medicine, 2002
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine, 1994